Blood-Pressure Drug Studied As Alzheimer’s Disease Treatment

Swedish Study Shows Promising Results On New Treatment

Editor’s Note: To date, there is no cure for Alzheimer’s disease and other forms of deadly prion disease. Unfortunately, little effort is being spent investigating all causes of this epidemic. Although we believe that there are multiple causes, reckless policies around the world are contributing to an unstoppable environmental pathogen that is spreading further every day. Our E-book discusses several causes of the disease and sources of the pathogen. Please join us and advocate for the truth and reform.

Alzheimer's disease treatment

A new European study is investigating whether the drug ‘nilvadipine,’ which is used to treat patients with high blood pressure, can effectively treat people with Alzheimer’s disease. This Swedish study is led by the Sahlgrenska Academy and Sahlgrenska University Hospital.

Nilvadipine obstructs the formation of amyloid plaques in animal brains. The drug will go on trial with 500 patients from across nine different European countries.

“Should this clinical trial be successful, nilvadipine would become the first Alzheimer’s drug that not only reduces the symptoms of the disease but also acts on its causes. This could dramatically reduce Europe’s costs for caring for patients with this neurodegenerative disease,” says Anne Börjesson-Hanson, a researcher at Sahlgrenska Academy, University of Gothenburg, who is leading the Swedish participation in the study.

treat Alzheimer's disease

During the trial, the patients will be treated with either nilvadipine or a placebo. The duration of the treatment is 18 months. If patients are already on medicines for Alzheimer they can continue taking the medicine. The team plans on conducting a follow up at the memory clinic at Sahlgrenska University Hospital. Researchers will conduct repeated tests on the subjects to determine if the drug causes changes in memory and cognition.


Leave a Reply

Your email address will not be published. Required fields are marked *